Conduit Pharmaceuticals INC Form 4 insider transactions

Jennifer Isacoff McNealey, a director of Conduit Pharmaceuticals, reports the acquisition of stock options.

David Tapolczay, CEO of Conduit Pharmaceuticals, reports the acquisition and disposal of warrants related to the company's common stock.

Director Freda Lewis-Hall and related entities acquire warrants in Conduit Pharmaceuticals in exchange for a one-year lock-up of common stock and a payment of $0.125 per warrant.

Chele Chiavacci Farley, a director of Conduit Pharmaceuticals, acquired warrants through an exchange and a private transaction, increasing her potential holdings of common stock.